Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
单位：[1]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China江苏省人民医院[2]Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China华中科技大学同济医学院附属同济医院[4]Nanjing Med Univ, Nanjing Hosp, Nanjing, Jiangsu, Peoples R China[5]China Med Univ, Affiliated Hosp 1, Shenyang 110001, Peoples R China[6]Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China[7]Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China四川大学华西医院[8]Secondary Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China[9]Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China[10]Yangzhou Univ, Clin Med Coll, Yangzhou 225009, Jiangsu, Peoples R China[11]Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China[12]Jiangning Hosp, Nanjing, Jiangsu, Peoples R China
Purpose: This prospective phase II, open label, study was designed to assess the efficacy and safety of D-CAG induction treatment for elderly patients with newly diagnosed AML. Experimental Design: All patients in this study were treated with decitabine of 15 mg/m(2) for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m(2) q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG). Results: Among 85 evaluable patients, overall response rate (ORR) and complete remission (CR) were 82.4% and 64.7%, respectively, after 1 cycle of therapy. The ORR in patients aged <70 years was 83.0% and 81.6% in patients aged >= 70 years. There was a significantly longer median overall survival (OS) in patients with response (16 months) than in those without response (7 months, p<0.0001). The OS for patients aged >= 70 years and 60-69 years was 10 months and 12 months, respectively (p=0.4994). The two-year OS probability was 19.2% and the twenty-month survival rate was 33.8%. Induction mortality of D-CAG treated elderly patients with AML is 4.4%. Conclusion: D-CAG regimen was well tolerated and showed a promising clinic efficacy in elderly patients with AML (>= 70 years).
基金：
National Natural Science Foundation of the People's Republic of China [81070437, 81270614, 81200362, 81070456, 81270652]; National Public Health Grand Research Foundation [201202017]; Priority Academic Program Development of Jiangsu Higher Education Institute [JX10231801]; Jiangsu Province Health Agency [K201107]; Jiangsu TePin Professor Program, Department of Education of Jiangsu Province; Jiangsu TePin Medical Expert Program, Health and Family Planning Commission of Jiangsu Province
第一作者单位：[1]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China[2]Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China
通讯作者：
通讯机构：[1]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China[2]Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China
推荐引用方式(GB/T 7714)：
Li Jianyong,Chen Yaoyu,Zhu Yu,et al.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia[J].ONCOTARGET.2015,6(8):6448-6458.doi:10.18632/oncotarget.3361.
APA：
Li, Jianyong,Chen, Yaoyu,Zhu, Yu,Zhou, Jianfeng,Xu, Yanli...&Qian, Sixuan.(2015).Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.ONCOTARGET,6,(8)
MLA：
Li, Jianyong,et al."Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia".ONCOTARGET 6..8(2015):6448-6458
